The Financial Times &amp; McKinsey Business Book of the Year A New York Times Notable Book A Washington Post Notable Book One of the Best Books of the Year: NPR, San Francisco Chronicle, Time, Esquire, Fortune, Marie Claire, GQ, Mental Floss, Science Friday, Bloomberg, Popular Mechanics, BookRiot, The Seattle Times, The Oregonian, Publishers Weekly, Library Journal In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup “unicorn” promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.5 billion. There was just one problem: The technology didn’t work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings—from journalists to their own employees. Rigorously reported and fearlessly written, Bad Blood is a gripping story of the biggest corporate fraud since Enron—a tale of ambition and hubris set amid the bold promises of Silicon Valley.

Bad Blood: Secrets and Lies in a Silicon Valley Startup

Business & Money

Carreyrou, John

Finance

Vintage

NEW YORK TIMES BEST SELLER • NAMED ONE OF THE BEST BOOKS OF THE YEAR BY: NPR, The New York Times Book Review, Time, Wall Street Journal, Washington Post • The McKinsey Business Book of the Year The full inside story of the breathtaking rise and shocking collapse of Theranos, the one-time multibillion-dollar biotech startup founded by Elizabeth Holmes—now the subject of the HBO documentary The Inventor—by the prize-winning journalist who first broke the story and pursued it to the end. “The story is even crazier than I expected, and I found myself unable to put it down once I started. This book has everything: elaborate scams, corporate intrigue, magazine cover stories, ruined family relationships, and the demise of a company once valued at nearly $10 billion.” —Bill Gates In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup “unicorn” promised to revolutionize the medical industry with a machine that would make blood testing significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.7 billion. There was just one problem: The technology didn’t work. A riveting story of the biggest corporate fraud since Enron, a tale of ambition and hubris set amid the bold promises of Silicon Valley.

Random House Audio |

KNOPF

Bad Blood

NATIONAL BESTSELLER - The gripping story of Elizabeth Holmes and Theranos--one of the biggest corporate frauds in history--a tale of ambition and hubris set amid the bold promises of Silicon Valley, rigorously reported by the prize-winning journalist. With a new Afterword. "Chilling ... Reads like a thriller ... Carreyrou tells [the Theranos story] virtually to perfection." --The New York Times Book Review In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes's worth at an estimated $4.5 billion. There was just one problem: The technology didn't work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings--from journalists to their own employees.

Turtleback Books

Random House, Large Print

En 2015, la fondatrice et CEO de Theranos, Elizabeth Holmes, était perçue comme un Steve Jobs au féminin : sa start-up promettait de révolutionner le secteur médical grâce à une machine qui permettrait de réaliser des analyses de sang plus facilement et plus rapidement. Theranos était évalué à 9 milliards de dollars lors de son ultime levée de fonds, à l’issue de laquelle Holmes elle-même pesait quelques 4,5 milliards de dollars. Un seul petit détail venait assombrir le tableau : la technologie Theranos ne fonctionnait pas.\nPendant des années, Holmes a menti à ses investisseurs et à ses partenaires commerciaux. Afin de dissimuler les défauts et les limites de ses machines, Theranos réalisait la majeure partie de ses analyses sur des appareils achetés dans le commerce, dans le plus grand secret. Pendant ce temps-là, Holmes entretenait dans l’entreprise une atmosphère de travail toxique, et régulièrement les employés de Theranos voyaient leurs collègues renvoyés du jour au lendemain pour avoir fait part de leurs doutes à la direction. Cette imposture allait produire un peu moins d’un million de faux résultats d’analyse, certains mettant sérieusement en péril la santé de patients.\nBad Blood raconte l’histoire captivante du plus gros scandale industrie depuis Enron, à travers un récit édifiant tissé autour de promesses imprudentes et de l’ivresse financière de la Silicon Valley.

Bad blood

Larousse

Bad Blood: Die wahre Geschichte des größten Betrugs im Silicon Valley - Ein SPIEGEL-Buch

Deutsche Verlags-Anstalt

Bad Blood (Japanese Edition)

Shueisha

Product Description En 2014 Elizabeth Holmes era considerada como la mujer Steve Jobs: una brillante alumna que abandonó Stanford, cuyo mágica nueva empresa prometía revolucionar la industria médica con una máquina que haría las pruebas de sangre significativamente más rápidas y fáciles. Respaldados por inversionistas importantes, Theranos vendió acciones en una ronda de recaudación que valoró a la compañía en más de 9.000 millones. Solo había un problema: la tecnología no funcionaba. Durante años, Holmes había engañado a inversionistas, funcionarios de la FDA y a sus empleados. Cuando John Carreyrou destapó escándalo en 2015 en el Wall Street Journal fueron amenazados con demandas. En 2017 el valor de la compañía era cero y Holmes se enfrentaba a una acción legal potencial del gobierno e inversionistas. About the Author Periodista franco-estadounidense que trabaja para The Wall Street Journal desde 1999 desde distintas ciudades como Bruselas, París y Nueva York. En 2008 fue nombrado jefe de la Oficina de Salud y Ciencia en Nueva York. Junto a un equipo del Journal, Carreyrou ganó el Pulitzer en 2003 por una serie de historias que expusieron varios escándalos corporativos en Estados Unidos y 2015, junto al Premio Gerald Loeb de Investigación, por Medicare Unmasked. También ha ganado los Premios Junior y Senior Peter R. Weitz del German Marshall Fund y el Premio George Polk, categoría Información Financiera.

Mala sangre

Literature & Fiction

Essays & Correspondence

Capitán Swing

See the best price to sell, buy, or rent books by Carreyrou, John. BookScouter helps to compare book prices from 25+ online bookstores and 30+ buyback vendors with a single search.

Books by Carreyrou, John